Wiese, W.; Siwecka, N.; Wawrzynkiewicz, A.; Rozpędek-Kamińska, W.; Kucharska, E.; Majsterek, I.
IRE1α Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies. Cancers 2022, 14, 2526.
https://doi.org/10.3390/cancers14102526
AMA Style
Wiese W, Siwecka N, Wawrzynkiewicz A, Rozpędek-Kamińska W, Kucharska E, Majsterek I.
IRE1α Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies. Cancers. 2022; 14(10):2526.
https://doi.org/10.3390/cancers14102526
Chicago/Turabian Style
Wiese, Wojciech, Natalia Siwecka, Adam Wawrzynkiewicz, Wioletta Rozpędek-Kamińska, Ewa Kucharska, and Ireneusz Majsterek.
2022. "IRE1α Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies" Cancers 14, no. 10: 2526.
https://doi.org/10.3390/cancers14102526
APA Style
Wiese, W., Siwecka, N., Wawrzynkiewicz, A., Rozpędek-Kamińska, W., Kucharska, E., & Majsterek, I.
(2022). IRE1α Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies. Cancers, 14(10), 2526.
https://doi.org/10.3390/cancers14102526